“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

I. Vaxman, J. Abeykoon, A. Dispenzieri, S. K. Kumar, F. Buadi, M. Q. Lacy, D. Dingli, Y. Hwa, A. Fonder, M. Hobbs, C. Reeder, T. Sher, S. Hayman, T. Kourelis, R. Warsame, E. Muchtar, N. Leung, R. Go, W. Gonsalves, M. SiddiquiR. A. Kyle, S. V. Rajkumar, McCullough C. Kristen, P. Kapoor, M. A. Gertz

Research output: Contribution to journalArticlepeer-review

Abstract

Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical trials. We report the outcomes of 36 patients treated at Mayo Clinic. Our cohort received a median of eight prior lines of therapy. Six patients received belantamab in combination with other medications (pomalidomide, cyclophosphamide, thalidomide), 13 patients (36%) were 70 years or older, two patients had a creatinine of >2.5 mg/dL, and one patient was on dialysis. All three patients with renal failure received full dose belantamab. Chimeric antigen receptor (CAR-T) therapy was used prior to belantamab in seven patients and none of them responded to belantamab therapy. The overall response rate (ORR) was 33% (CR 6%, VGPR 8%, PR 19%), like the ORR reported in the DREAMM-2 trial. Keratopathy developed in 16 patients (43%), grade 1 in six patients, grade 2 in seven patients, and grade 3 in three patients. Eight percent discontinued therapy due to keratopathy. The median PFS and OS was 2 months and 6.5 months, respectively.

Original languageEnglish (US)
Article number196
JournalBlood cancer journal
Volume11
Issue number12
DOIs
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of '“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience'. Together they form a unique fingerprint.

Cite this